Efficacy And Safety Of Three Adjuvant Chemotherapies Based On Oxaliplatin And Fluorouracil In The Treatment Of Advanced Gastric Cancer

Ojective: In recent years,with the advent of gene sequencing technology,biological analysis technology and the emergence of large data analysis tools,medicine was pushed into the era of precision medicine.Affected by this new treatment mode,advanced gastric cancer treatment by surgery alone before the treatment mode for the surgical treatment of postoperative adjuvant therapy + current,emphasizes precise medication radical surgery and adjuvant chemotherapy.Through the retrospective comparison with oxaliplatin combined with fluorouracil based adjuvant chemotherapy on three patients with curative effect and adverse reactions of radical operation in the treatment of advanced gastric cancer after the study.To evaluate the efficacy and safety of three adjuvant chemotherapy regimens in the treatment of patients with advanced gastric cancer.Methods: A retrospective analysis from April 2004 to November 2009 Fourth in Hebei Medical University hospital from 634 cases of patients with gastric carcinoma confirmed by pathology,all patients underwent radical surgery for gastric cancer,adjuvant treatment 6 treatment after operation.634 patients were divided into 3 groups,divided into the following groups according to the program,including XELOX group of 112 cases,mFLO group of 220 cases,FOLFOX4 group of 302 cases.All the cases were followed up in November 2009,followed up for 25~80 months,with a median follow-up of 35 months(months).The disease-free survival time(DFS),overall survival time(OS)and adverse reactions were compared between the three groups.Results:1 104 patients were lost during follow-up,530 patients had complete follow-up data,XELOX group,mFLO group and FOLFOX4 group,the median disease-free survival time were 32.6 months,25.2 months and 28.8 months,the three groups had no statistically significant difference(P>0.05).The median overall survival time of the three groups was 43.2 months,40.7 months and 39.5 months respectively,and the difference was not statistically significant(P>0.05).The median disease-free survival time and median overall survival time of XELOX group were slightly higher than those of group mFLO and group FOLFOX4,but there was no significant difference between the two groups(P>0.05).2 There were two kinds of adverse reactions in the three groups,,hematologic adverse reactions between the three groups had no significant difference in nonhematologic adverse reactions,XELOX group in the incidence of diarrhea was significantly lower than that of mFLO group and FOLFOX4 group,with statistical difference(P=0.01<0.05,P=0.037<0.05),XELOX group and FOLFOX4 group in peripheral neurotoxicity the rate was significantly lower than mFLO group,with statistical difference(P=0.001 <0.05,P=0.003<0.05),the adverse reactions could be tolerated.Conclusion:1 There were no significant differences in DFS and OS between the three chemotherapy regimens of XELOX,mFLO and FOLFOX4 in postoperative adjuvant chemotherapy of gastric cancer.2 Combined with toxic side effects,XELOX program is more convenient,better tolerated and safer than the other two groups,which is worthy of clinical promotion and application.